EC has authorized SKYCLARYS® for the treatment of Friedreich’s ataxia in adults and adolescents aged 16 years and older
Biogen announced the European Commission (EC) has authorized SKYCLARYS® (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents aged 16 years and older. 👉 SKYCLARYS is the first treatment approved within the European Union for this rare,…